Investegate |Santhera Pharmaceuticals Holdi Announcements |

Investegate announcements from Santhera Pharmaceuticals Holdi, European Medicines Agency Validates Santhera’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

Related Keywords

Norway , Iceland , Pratteln , Switzerland General , Switzerland , United States , United Kingdom , Liechtenstein , France , America , Swiss , Shabir Hasham , Eric Hoffman , Eva Kalias , Reveragen Biopharma , Life Science Alliance , Muscular Dystrophy Association United States , Santhera Pharmaceuticals Holding , Head Investor Relations Communications , European Union , Committee For Medicinal Products Human Use , Santhera Pharmaceuticals , National Institutes Of Health , Drug Administration , Foundation To Eradicate Duchenne , Duchenne Research Fund , European Commission , European Commission Horizons , Chiesi Group , European Medicines Agency , Us Department Of Defense , European Medicines Agency Validates Santhera , Marketing Authorization Application , Duchenne Muscular , Medicinal Products , Human Use , Orphan Drug , Fast Track , Rare Pediatric Disease , Promising Innovative Medicine , Proc Natl Acad Sci United States , North America , Parent Project Muscular Dystrophy , Eradicate Duchenne , Save Our Sons , Action Duchenne , Defeat Duchenne , National Institutes , Head Investor Relations , Investegate Announcements , Investegate Company Announcements , Anthera Pharmaceuticals Holdi , Lobenewswire , Lobenewswire And Globenewswire , Nw ,